Prognostic Influence of Increased C-Reactive Protein and Fibrinogen Levels in Ischemic Stroke
暂无分享,去创建一个
[1] M. Di Napoli,et al. C-reactive protein and outcome after first-ever ischemic stroke. , 2000, Stroke.
[2] V. Bocola,et al. C-Reactive Protein After First-Ever Ischemic Stroke , 1999 .
[3] M. Moskowitz,et al. Pathobiology of ischaemic stroke: an integrated view , 1999, Trends in Neurosciences.
[4] K. Lees,et al. C-reactive protein and outcome after ischemic stroke. , 1999, Stroke.
[5] D. Briley,et al. Persistent inflammatory response in stroke survivors , 1998, Neurology.
[6] R. Tracy. Inflammation in cardiovascular disease: cart, horse, or both? , 1998, Circulation.
[7] C. Marini,et al. High stroke incidence in the prospective community-based L'Aquila registry (1994-1998). First year's results. , 1997, Stroke.
[8] A. Grau. Infection, inflammation, and cerebrovascular ischemia , 1997, Neurology.
[9] M. Dennis. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .
[10] David Schultz,et al. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996, The Lancet.
[11] W. Feinberg,et al. Hemostatic markers in acute ischemic stroke. Association with stroke type, severity, and outcome. , 1996, Stroke.
[12] MichalBenderly,et al. Fibrinogen Is a Predictor of Mortality in Coronary Heart Disease Patients , 1996 .
[13] I. Sartori. Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina Pectoris , 1996 .
[14] D. Clement. A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .
[15] P. Savage,et al. Fibrinogen and factor VIII, but not factor VII, are associated with measures of subclinical cardiovascular disease in the elderly. Results from The Cardiovascular Health Study. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[16] A. Simon,et al. Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[17] B. Coull,et al. Interleukin‐6 and interleukin‐1 receptor antagonist in acute stroke , 1995, Annals of neurology.
[18] F. Galetta,et al. [Fibrinogen as a cardiovascular risk factor]. , 1995, Minerva cardioangiologica.
[19] G. Assmann,et al. Association of Variables of Coagulation, Fibrinolysis and Acute-phase with Atherosclerosis in Coronary and Peripheral Arteries and those Arteries Supplying the Brain , 1995, Thrombosis and Haemostasis.
[20] G. Assmann,et al. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[21] G. Vercellotti,et al. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor , 1993 .
[22] E. Ernst,et al. Fibrinogen as a Cardiovascular Risk Factor , 1993, Annals of Internal Medicine.
[23] Harry,et al. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. , 1993, Blood.
[24] A. Banerjee,et al. A Six Year Prospective Study of Fibrinogen and Other Risk Factors Associated with Mortality in Stable Claudicants , 1992, Thrombosis and Haemostasis.
[25] E. Ernst,et al. Fibrinogen and Viscosity as Risk Factors for Subsequent Cardiovascular Events in Stroke Survivors , 1992, Annals of Internal Medicine.
[26] M. Burr,et al. Haematological prognostic indices after myocardial infarction: evidence from the diet and reinfarction trial (DART). , 1992, European heart journal.
[27] M. Burr,et al. Influence of platelet size on outcome after myocardial infarction , 1991, The Lancet.
[28] J. Bamford,et al. Classification and natural history of clinically identifiable subtypes of cerebral infarction , 1991, The Lancet.
[29] P C Elwood,et al. Fibrinogen, Viscosity, and White Blood Cell Count Are Major Risk Factors for Ischemic Heart Disease: The Caerphilly and Speedwell Collaborative Heart Disease Studies , 1991, Circulation.
[30] Daniel B Hier,et al. The Stroke Data Bank: design, methods, and baseline characteristics. , 1988, Stroke.
[31] V. Nguyen. Fibrinogen and risk of cardiovascular disease: Kannel WB, Wolf PA, Castelli WP, et al JAMA 258: 1183–1186 Sep 1987 , 1988 .
[32] R. D'Agostino,et al. Fibrinogen and risk of cardiovascular disease. The Framingham Study. , 1987, JAMA.
[33] R Côté,et al. The Canadian Neurological Scale: a preliminary study in acute stroke. , 1986, Stroke.
[34] M. C. Stone,et al. Plasma fibrinogen--a major coronary risk factor. , 1985, The Journal of the Royal College of General Practitioners.
[35] J. Volanakis. COMPLEMENT ACTIVATION BY C‐REACTIVE PROTEIN COMPLEXES * , 1982, Annals of the New York Academy of Sciences.
[36] J. Kostis,et al. Association of recurrent myocardial infarction with hemostatic factors: a prospective study. , 1982, Chest.
[37] S. Thompson,et al. HÆMOSTATIC FUNCTION AND CARDIOVASCULAR DEATH: EARLY RESULTS OF A PROSPECTIVE STUDY , 1980, The Lancet.
[38] S. Thompson,et al. Haemostatic function and cardiovascular death: early results of a prospective study. , 1980, Lancet.
[39] Classification and Diagnosis of Diabetes Mellitus and Other Categories of Glucose Intolerance , 1979, Diabetes.
[40] F. Mahoney,et al. FUNCTIONAL EVALUATION: THE BARTHEL INDEX. , 2018, Maryland state medical journal.
[41] Mahoney Fi,et al. FUNCTIONAL EVALUATION: THE BARTHEL INDEX. , 1965 .